Glenmark Pharmaceuticals Ltd Q3 FY26 Earnings Analysis
Published 3 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹63.7K Cr
Price
₹2,340
Market Cap
₹63.7K Cr
P/E Ratio
20.4
Earnings Summary
TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). - FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17). - India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17). - Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10). - Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9). - U.S. FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products. - EBITDA margins expected to expand beyond current guidance due to increasing branded mix, emerging market strength, and operating leverage from fixed cost base. - India business projected to sustain strong growth with a 19% growth in December vs.
📊 Revenue & Sales Performance
- →TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17).
- →FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17).
- →India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17).
- →Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10).
- →Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9).
- →U.S. expected to have a strong finish in FY '26 with new respiratory launches anticipated in Q4; Monroe plant to contribute with new product approvals (Pages 7, 9).
- →Overall, strong growth outlook with expansion into innovative branded assets and emerging markets (Pages 7, 17).
📈 Profitability & Margins
- →FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products.
- →EBITDA margins expected to expand beyond current guidance due to increasing branded mix, emerging market strength, and operating leverage from fixed cost base.
- →India business projected to sustain strong growth with a 19% growth in December vs. 10-11% market growth, supported by chronic respiratory and oncology launches.
- →Europe to grow at high single to low double digit in constant currency, supported by upcoming respiratory product launches and RYALTRIS sales.
- →Specialty and innovative portfolio (e.g., oncology assets like TEVIMBRA, BRUKINSA) expected to have higher gross and EBITDA margins, contributing to margin uplift from FY '28 onwards.
- →Capex maintained at INR800 crores annually to support commercial and R&D expansions, aiding growth trajectory.
- →Ichnos-related revenues stable at $70 million annualized.
- →Overall, Glenmark aims to continue strong earnings growth and margin improvement while moving up the value chain with next 5-10 year innovation focus.
🏗️ Capital Expenditure Plans
- →Planned capex for the next fiscal year is around INR 700-800 crores annually.
- →Investments primarily go into:
- → - Ongoing capex on plants and expanding current manufacturing lines and facilities.
- → - Strategic in-licensing products such as the Hengrui asset.
- →No current in-house biologic manufacturing; biologics manufacturing is outsourced, but future developments unknown.
- →Capex mix: approximately 55% intangible assets (e.g., licensing, product acquisition) and 45% tangible assets (e.g., plant expansion).
- →Capex for the recent quarter was around INR 215 crores, with year-to-date capex at INR 715 crores.
- →The company is focused on complex injectable products and expanding filing activity at manufacturing sites for growth.
- →No specific disclosures on additional partnering timelines or deal scopes for current assets related to capex investments.
💰 Fundraising & Capital Structure
- →There is no specific mention or visibility provided on any upcoming new fundraising through debt or equity in the provided document pages.
- →The company remains net cash positive with around INR600 crores net cash and gross debt close to INR600 crores as of December 31, 2025.
- →Capex for the next fiscal year is planned around INR700-800 crores, mostly for plant expansions and in-licensing products, but no mention of raising new funds for these.
- →Management emphasizes managing working capital efficiently and maintaining financial health but does not indicate plans for additional debt or equity fundraising.
- →Partnership discussions focus more on optimal timing rather than immediate capital raising through public or private markets.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Glenmark Pharmaceuticals Ltd Q3 FY26 results?
TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). - FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17). - India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17). - Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10). - Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9). - U.S. FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products. - EBITDA margins expected to expand beyond current guidance due to increasing branded mix, emerging market strength, and operating leverage from fixed cost base. - India business projected to sustain strong growth with a 19% growth in December vs.
What is Glenmark Pharmaceuticals Ltd share price analysis?
Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹63,749 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharmaceuticals Ltd planning capital expenditure?
Planned capex for the next fiscal year is around INR 700-800 crores annually.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.